377P - Overall prognosis of advanced breast cancer (ABC) according to chemotherapy (CT) treatment lines: correlation analysis between progression-free-, p...

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer, Metastatic
Presenter Rosachiara Forcignano`
Citation Annals of Oncology (2014) 25 (suppl_4): iv116-iv136. 10.1093/annonc/mdu329
Authors R. Forcignano`1, E. Bria2, A. Fabi3, L. Petrucelli1, J. Furlanetto4, L. Carbognin4, A. Gambino1, C. Vicentini2, V. Saracino1, L. Lupo1, V.E. Chiuri1, G. Cairo1, G. Tortora5, E. De Matteis1, G. Ronzino6, A. Tornesello1, I. Sperduti7, D. Giannarelli7, M. Ciccarese8
  • 1Oncology, "Vito Fazzi" Hospital, 73100 - Lecce/IT
  • 2Medical Oncology, Azienda Ospedaliera Universitaria Integrata Verona - "Borgo Roma", 37134 - Verona/IT
  • 3Divisione Di Oncologia Medica A, Istituto Nazionali Tumori Regina Elena, Rome/IT
  • 4Medical Oncology, Azienda Ospedaliera Universitaria Integrata Verona-"Borgo Roma", 37134 - Verona/IT
  • 5Oncologia Medica, Azienda Ospedaliera Universitaria Integrata Verona-"Borgo Roma", 37134 - Verona/IT
  • 6Oncology And Haematology, Ospedale Vito Fazzi, IT-73100 - Lecce/IT
  • 7Biostatistics, Regina Elena National Cancer Institute, 00144 - Roma/IT
  • 8Oncology Dept., Ospedale Vito Fazzi, 73100 - Lecce/IT

Abstract

Aim

ABC remains an incurable disease although the introduction of targeted agents and newest drugs has significantly improved the overall outcome. Nevertheless, the degree of the benefit provided by CT beyond the 3rd line is controversial.

Methods

Data of consecutive ABC patients (pts) were retrospectively gathered, according to pathological subtype (Ki67 < 20%: Luminal A, Luminal B: Ki67 ≥ 20%; HER2-positive, and triple negative) and clinical factors. The hazard ratio (HR) and the 95% confidence intervals (95% CI) were estimated using the Cox uni- and multivariate proportional model. The log-rank analysis for PFS, PPS and OS was used; the correlation between outcomes was performed as well.

Results

The characteristics of 485 pts from 3 different institutions were: median age: 60 years (29-91); median time from primary: 29 months (0-721), median number of sites: 2 (1-6); visceral/bone only disease: 300 (62%)/125 (26%); Luminal A/B/HER2-positive/triple-negative/non-evaluable: 92 (19%)/124 (25%)/117 (24%)/41 (9%)/111 (23%); median number of CT lines: 2 (1-12); overall OS: 45 months (95% CI 34-56). Age (HR 1.01, 95% CI 1.01-1.03, p = 0.04), <2 metastatic sites (HR 1.58, 95% CI 1.14-2.21, p = 0.01), low Ki67 (HR 1.62, 95% CI 1.14-2.29, p = 0.01), and treatment with hormonal therapy (HR 2.06, 95% CI 1.49-2.87, p < 0.01) were independent predictors of longer OS at the multivariate analysis. Median OS according for subtypes was: Luminal A 48 months (95% CI 34-56), Luminal B 37 (95% CI: 28-42), HER2-positive 39 (95% CI 30-44), and triple-negative 15 (95% CI: 11-29). Patients receiving ≥3 CT lines fared significantly better than those undergone <3 lines (50 months [95% CI 46-55] vs 29 [95% CI 31-39], p < 0.0001). Both PFS and PPS were significantly correlated with OS from 1st to 6th line (p < 0.0001), with a trend from 7th to 8th (PFS: p = 0.45 and p = 0.03; PPS: p = 0.003 and p = 0.07, respectively).

Conclusions

These data suggest that CT beyond 3rd line may potentially have a significant impact upon survival. The correlation between OS and both PPS and PFS is consistently maintained across all treatment lines.

Disclosure

All authors have declared no conflicts of interest.